華潤三九(000999.SZ)披露29.02億元資產併購草案 將入主昆藥集團
格隆匯11月29日丨華潤三九(000999.SZ)披露重大資產購買報吿書(草案),公司擬以支付現金的方式向華立醫藥購買其所持昆藥集團約2.09億股股份(佔昆藥集團已發行股份總數的27.56%),並向華立集團購買其所持昆藥集團約333.55萬股股份(佔昆藥集團已發行股份總數的0.44%)。
該次交易完成後,公司將合計持有昆藥集團約2.12億股股份(佔昆藥集團已發行股份總數的28%),成為昆藥集團的控股股東,上述標的股份價格擬定為人民幣29.02億元,對應昆藥集團每股轉讓價格為人民幣13.67元/股。
公司表示,其將在原有業務基礎上,進一步拓寬主要產品矩陣,補充傳統國藥品牌,尤其是以三七和青蒿為原材料的天然植物藥產品。後續昆藥集團將在華潤三九良好的品牌運作能力基礎上,探索將“昆中藥1381”、“昆中藥”打造為精品國藥品牌,以此承載更多具有歷史沉澱的產品,並有利於推動以三七為代表的中醫藥產業鏈高質量發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.